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Table  1  Diagnostic  parameters  of  different  pleural  ﬂuid  characteristics.
40  U/L  40  U/L  +  >50%lymph.  74.6  U/L  +  >50%lymph.
Sensitivity  (%,  95%CI)  95.24  (76.11--99.21)  95.00  (75.05--99.17)  75.00  (50.89--91.25)
Speciﬁcity  (%,  95%CI)  91.95  (84.12--96.69)  95.40  (88.63--98.71)  98.85  (93.74--99.81)
PPV (%,  95%  CI)  74.07  (53.71--88.84)  82.61  (61.20--94.94)  93.75  (69.69--98.86)
NPV (%,  95%CI)  98.77  (93.29--99.79)  98.81  (93.52--99.80)  94.51  (87.63--98.17)
PPV: positive predictive value; NPV: negative predictive value; lymph.: lymphocytes.
performance  of  the  cutoff  value  of  40  U/L  and  the  error
rate  of  4.5%  (for  ADA  >  40  U/L  and  >50%  lymphocytes)  and
1.1%  (for  ADA  <  74.6  U/L  and  >50%  lymphocytes)  is  in  line
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6with  other  publications. In  our  analysis,  one  patient  with
pleural  TB  had  an  ADA  level  <  40  U/L;  however,  in  a  sample
collected  just  3  days  later,  ADA  level  was  now  90  U/L  which
reafﬁrms  the  diagnostic  utility  of  ADA.  Also,  as  we  have
shown,  hematological  malignancies  are  frequent  causes  of
error,  and  they  should  be  excluded  by  this  analysis  of  the
pleural  lymphocyte  populations.2,6 However,  the  usefulness
of  ADA  in  the  diagnosis  of  tuberculous  effusions  depends  on
the  prevalence  of  the  disease  in  the  population.2 If  tuber-
culosis  is  highly  prevalent,  as  in  the  African  continent  and
Southeast  Asia,  then  a  high  value  of  pleural  ADA  is  more
likely  to  be  due  to  tuberculosis,  thus  increasing  the  PPV  of
pleural  ADA  in  the  diagnosis  of  pleural  TB.  If,  however,  the
disease  is  less  prevalent,  the  probability  of  a  high  ADA  being
due  to  other  causes,  such  as  cancer,  increases,  and  PPV  of
pleural  ADA  is  lower.  This  is  most  evident  in  countries  with  a
low  prevalence  of  tuberculosis  and  an  aging  population,  as
it  is  in  old  age  that  malignant  effusions  are  more  prevalent.
In  conclusion,  pleural  ADA  is  a  valuable  tool  in  the  diag-
nostic  workup  of  pleural  TB  in  Portugal  and  should  routinely
be  used  in  the  exclusion  or  conﬁrmation  of  TB  in  the  dif-
ferential  diagnosis  of  patients  with  a  pleural  effusion  of
unknown  cause.  Furthermore,  in  order  to  make  a  correct
interpretation  of  its  values,  we  have  highlighted:  potential
false-positives;  the  usefulness  of  different  ADA  cutoffs  for
the  exclusion  or  conﬁrmation  of  TB;  and  the  impact  of  TB
prevalence  on  the  predictive  parameters  of  this  tool.
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EBUS in pulmonary sarcoidosis:
What to expect?
EBUS (ecograﬁa endobrônquica) na sarcoidose
pulmonar: o que esperar?
Dear  Editor,
The  utility  of  EBUS-TBNA  in  the  diagnosis  of  sarcoidosis  has
recently  been  reported.1,2 Studies  published  have  shown  a
higher  diagnostic  yield  in  favour  of  EBUS-TBNA,  compared  to
standard  bronchoscopic  diagnostic  techniques,  particularly
for  stage  I  sarcoidosis.3--6 The  main  advantages  identiﬁed,
beside  the  high  diagnostic  yield,  are  the  low  complication
rate  and  being  able  to  avoid  invasive  procedures,  like  medi-
astinoscopy.
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Several  recent  editorials  reviewed  the  value  of  EBUS-
BNA  in  excluding  other  diagnoses  in  patients  with
uspected  sarcoidosis.  In  a recent  editorial  published  in
he  Journal  of  Bronchology  and  Intervention  Pulmonology,
eich  and  colleagues  estimated  that  10,000  patients  with
tage  I  sarcoidosis  would  have  to  be  submitted  to  an
nvasive  diagnostic  procedure  to  identify,  at  most,  5  peo-
le  with  an  alternative  pathology,  and  questioned  the
eed  for  tissue  conﬁrmation  in  asymptomatic  stage  I
arcoidosis.7
Among  the  series  published  with  patients  in  suspected
tage  I and  II  sarcoidosis  that  have  undergone  EBUS-TBNA,
nly  10%  obtained  an  alternative  diagnosis.8 However,  these
lternative  diagnoses  should  not  be  ignored.  A  delay  in  this
ontext  can  be  harmful  to  the  patient.
What  data  exists  that  is  available  in  relation  to  these
uestions?
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Figure  1  Flowchart  showing  conﬁrmation  of  diagno
In  our  experience,  48  patients  with  clinical  and  radiolog-
cal  ﬁndings  suggestive  of  sarcoidosis  underwent  EBUS-TBNA
74%  stage  I  and  26%  stage  II;  mean  age  45  years).  Final  diag-
osis  of  sarcoidosis  was  established  in  81%  of  the  patients
39  of  48  patients).  The  diagnostic  yield  of  EBUS-TBNA  for
arcoidosis  was  73%,  with  a  sensitivity  and  speciﬁcity  of
7%  and  100%,  respectively.  The  negative  predictive  value
as  41%.  Nine  different  diagnoses  were  found:  silicosis
n  =  2),  tuberculosis  (n  =  3),  non-Hodgkin  lymphoma  (n  =  1)
nd  reactive  adenopathy  (n  =  3).  Thirteen  patients  received
he  ﬁnal  diagnosis  of  sarcoidosis  after  a  negative  EBUS-TBNA
esult.  Among  them,  an  additional  histological  biopsy  was
nly  performed  in  3  patients  (bronchial  biopsy,  peripheral
ymph  node  biopsy  (found  after  whole-body  gallium  scan)
nd  surgical  lung  biopsy).  In  the  remaining  10  patients,  9
ad  stage  I  sarcoidosis  and  1  had  asymptomatic  stage  II
arcoidosis,  the  diagnosis  was  supported  by  broncoalveo-
ar  lavage  (CD4+/CD8+  ratio  >  3.5),  radiologic  criteria  and  at
east  a  minimum  6  months  follow-up  (mean  19  ±  5.7  months)
Figure  1).
Tournoy  et  al.9 published  the  results  of  large  diagnos-
ic  algorithm  implementation  trial  for  sarcoidosis.  A  total  of
37  patients  were  included  (75%  stage  I).  Bronchoscopy  was
one  in  121  patients  establishing  the  deﬁnite  diagnosis  of
arcoidosis  in  57  cases  (42%).  The  sensitivity  of  endoscopic
ltrasound  following  non-diagnostic  standard  bronchoscopic
echniques  was  71%  and  endoscopic  ultrasound  prevented surgical  procedure  in  47  of  the  80  patients.  The  author
ound  that  by  adding  EBUS  +  EUS  to  prior  nondiagnostic iSilicosis
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 48  patients  with  suspected  stage  I  and  II  sarcoidosis.
ronchoscopy,  three  patients  had  to  be  investigated  in
rder  to  avoid  one  surgical  diagnostic  procedure.  Of  the  33
atients  left  without  pathological  conﬁrmation,  22  under-
ent  a  surgical  procedure  and  an  alternative  diagnosis  was
ound  in  only  6  patients.  The  other  11  patients  were  submit-
ed  to  clinical  surveillance.
Garwood  et  al.  included1 50  patients  with  suspected  sar-
oidosis  and  a  ﬁnal  diagnosis  of  sarcoidosis  was  conﬁrmed
n  48  patients  (one  patient  was  lost  to  follow-up).  The  diag-
ostic  yield  of  EBUS-TBNA  was  85%  (41  of  48  patients)  and
as  highest  in  stage  I,  followed  by  stage  II  disease  (94%
s.  80%  respectively).  When  EBUS-TBNA  result  was  negative
 further  histological  biopsy  was  performed  in  5  patients
EBUS-targeted  TBNA,  transbronchial  lung  biopsy  (TBLB)  or
upraclavicular  lymph  node  biopsy)  and  2  were  followed  up
linically.  No  patient  was  submitted  to  mediastinoscopy  and
o  alternative  diagnosis  was  found.
Wong  et  al.2 included  65  patients  with  clinical  and  radio-
ogical  ﬁndings  suggestive  of  sarcoidosis  (74%  stage  I).  The
ecision  to  proceed  to  TBLB  was  left  to  the  discretion  of  the
perators.  In  61  patients  the  ﬁnal  diagnosis  of  sarcoidosis
as  obtained,  56  by  EBUS-TBNA  and  5  by  mediastinoscopy.
hree  patients  with  indeﬁnite  diagnosis  were  followed  up  for
18  months  and  showed  no  clinical  or  radiological  deterio-
ation.  One  patient  underwent  video-assisted  thoracoscopic
urgery  (VATS),  after  an  inadequate  EBUS-TBNA  specimen,
hich  showed  Wegener’s  granulomatosis.
In  the  Granuloma  clinical  trial, 303  patients  with  a  clin-
cal  and  radiologic  suspicion  of  sarcoidosis  stage  I/II  (51%
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stage  I)  were  randomized:  149  to  conventional  bronchoscopy
and  155  to  endosonography.  The  ﬁnal  diagnosis  was  sarcoido-
sis  in  278  of  the  303  patients  (92%)  which  was  based  on
tissue-proven  granulomas  in  250  of  the  278  patients  (90%)
and  in  28  of  the  278  patients  (10%)  on  clinical  and  radiologic
follow-up.  For  stage  I  sarcoidosis,  endosonography  had  a  sig-
niﬁcantly  higher  diagnostic  yield  than  bronchoscopy  (84%
vs.  38%,  P  <  0.001).  For  stage  II  sarcoidosis,  the  difference
was  not  statistically  signiﬁcant  (66%  vs.  77%,  P  =  0.18).  In
the  bronchoscopy  group,  biopsies  demonstrated  eosinophilic
and  granulomatous  vasculitis  in  one  patient  and  metas-
tasized  thyroid  cancer  in  another.  In  the  endosonography
group,  non-caseating  granulomas  without  necrosis  were
found  in  2  patients,  of  whom  one  received  a  diagnosis
of  tuberculosis  and  the  other  of  metastasized  non-small
cell  lung  carcinoma.  In  2  more  patients,  a  non-small  cell
lung  carcinoma  and  colon  carcinoma  nodal  metastasis  were
found.
The  EBUS-TBNA  increases  the  diagnostic  yield  of  sar-
coidosis  (range  71--90%  in  the  studies  presented),  and
reduces  the  need  for  more  invasive  procedures.  In  every
study  illustrated  above,  alternative  diagnoses  were  obtained
in  a  minority  of  patients.  Similar  to  our  results,  all  authors
described  clinical  follow-up  as  an  alternative  to  invasive
methods  after  negative  EBUS-TBNA,
The  role  of  EBUS-TBNA  in  the  diagnosis  of  sarcoidosis  has
become  irreplaceable,  not  only  to  conﬁrm  the  diagnosis,
but  also  to  exclude  other  diseases,  especially  malignancy.
Nevertheless,  EBUS-TBNA  can  provide  additional  difﬁcul-
ties  when  a  differential  diagnosis,  such  as  lymphoma,  is
concerned,  and  in  these  cases  further  invasive  procedures
can  have  considerable  value.
In  our  experience,  there  was  no  question  of  performing
EBUS-TBNA,  since  tuberculosis  and  lymphoma  were  diag-
nosed.  On  the  other  hand,  among  negative  EBUS-TBNA
patients  who  did  not  perform  additional  investigations,  no
alternative  diagnosis  emerged.
Nowadays,  the  great  challenge  is  to  know  when  just  EBUS
is  enough  or  when  to  proceed  with  invasive  investigation.
What  is  the  correct  approach  after  an  EBUS-TBNA  negative
result?
In  our  opinion,  although  looking  for  granulomatous
inﬂammation  is  the  concern,  lymph  node  sampling  by  EBUS-
TBNA  can  give  us  signiﬁcant  information.  The  appropriate
patient  selection  is  the  key  for  the  use  of  EBUS-TBNA  in
sarcoidosis,  and  the  decision  to  proceed  to  further  investiga-
tion  must  be  based  in  the  pre-test  probability  of  sarcoidosis
vs.  alternative  diagnosis,  mainly  in  stage  I  sarcoidosis.  This
approach  should  be  prospectively  conﬁrmed.231
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